AMGN Stock Forecast: Amgen, Inc. Price Predictions for 2026-2027
The 34 Wall Street analysts covering Amgen, Inc. hold a median 12-month price target of $440 — +1.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 95 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Amgen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (98): The business earns solid, repeatable profits on what it owns.
Accruals (47): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
AMGN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AMGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1.0% from it.
Of the 20 most recent actions, 20 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | Barclays | Maintains | Equal-Weight | $400 → $430 |
| 12 Nov 2026 | Argus Research | Maintains | Buy | $460 → $515 |
| 6 Nov 2026 | Freedom Broker | Downgrade | Hold | $450 → $470 |
| 5 Nov 2026 | Guggenheim | Maintains | Neutral | $378 → $435 |
| 5 Nov 2026 | Leerink Partners | Maintains | Market Perform | $395 → $464 |
| 4 Nov 2026 | Bernstein | Maintains | Market Perform | $345 → $400 |
| 4 Nov 2026 | Canaccord Genuity | Maintains | Hold | $384 → $440 |
| 4 Nov 2026 | Cantor Fitzgerald | Maintains | Neutral | $440 → $465 |
| 4 Nov 2026 | Citigroup | Maintains | Neutral | $405 → $465 |
| 4 Nov 2026 | Goldman Sachs | Maintains | Buy | $481 → $536 |
| 4 Nov 2026 | JP Morgan | Maintains | Neutral | $350 → $425 |
| 4 Nov 2026 | Morgan Stanley | Maintains | Equal-Weight | $359 → $410 |
| 4 Nov 2026 | RBC Capital | Maintains | Outperform | $430 → $470 |
| 4 Nov 2026 | Scotiabank | Maintains | Sector Outperform | $500 → $530 |
| 4 Nov 2026 | TD Cowen | Maintains | Buy | $452 → $531 |
| 4 Nov 2026 | Truist Securities | Maintains | Hold | $380 → $398 |
| 4 Nov 2026 | UBS | Maintains | Buy | $470 → $530 |
| 4 Nov 2026 | Wells Fargo | Maintains | Equal-Weight | $430 → $460 |
| 23 Oct 2026 | Oppenheimer | Maintains | Outperform | $450 → $480 |
| 21 Oct 2026 | Barclays | Maintains | Equal-Weight | $380 → $400 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AMGN.
This page is one stock. Monday covers all of them.
AMGN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
AMGN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Amgen, Inc. returned +34.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
AMGN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 25.7×
- Price / sales
- 6.2×
- Price / book
- 16.7×
- EV / EBITDA
- 15.8×
Cheaper than 34% of US stocks
Cheaper than 18% of US stocks
Cheaper than 4% of US stocks
Cheaper than 31% of US stocks
- Revenue growth (YoY)
- 8.5%
- Earnings growth (YoY)
- 20.1%
- Gross margin
- 72.0%
- Operating margin
- 34.1%
- Net margin
- 24.1%
Higher than 50% of US stocks
Higher than 60% of US stocks
Higher than 84% of US stocks
Higher than 90% of US stocks
Higher than 84% of US stocks
- Return on equity
- 78.4%
- Return on assets
- 8.9%
- Dividend yield
- 2.3%
Higher than 95% of US stocks
Higher than 90% of US stocks
Higher than 48% of US dividend payers
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Amgen, Inc. has a market value of $237.4B and an enterprise value of $278.2B.
Revenue in the twelve months to 30 June 2026: $38.1B. The latest quarter grew 9.5% year on year.
Net income over the same four quarters: $8.7B, a 23.0% net margin.
Diluted earnings per share, trailing twelve months: $16.09.
Free cash flow in the twelve months to 30 June 2026: $10.2B.
Amgen, Inc. spent $5.3B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 25.7×; forward P/E: 17.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.29%, paying out 58% of earnings.
Amgen, Inc. employs 31,500 people — $1.2M of revenue per employee.
Data provided by Twelve Data
AMGN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at AMGN’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Amgen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about AMGN
What is the AMGN stock price forecast for 2026-2027?
The 34 Wall Street analysts covering Amgen, Inc. have a median 12-month price target of $440, with estimates ranging from $230 to $542. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AMGN stock a buy right now?
Of the 34 analysts covering Amgen, Inc., 11 rate it a Buy, 18 a Hold and 5 a Sell. Ticker Nerd's systematic factor model ranks Amgen, Inc. 95 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AMGN?
As at 21 Nov 2026, Amgen, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).
Will AMGN stock go up?
No one can know that. What the data says: the median 12-month target from 34 analysts implies +1.0% from the last close, and Ticker Nerd's factor model ranks Amgen, Inc. 95 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AMGN stock forecast for 2030?
No analyst covering Amgen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $230 to $542 over the next 12 months.
How has AMGN stock performed over the past year?
Amgen, Inc. returned +34.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Amgen, Inc. do?
Amgen Inc. Common Stock represents ownership in Amgen Inc., a biotechnology company focused on discovering, developing, manufacturing, and marketing human therapeutics for serious diseases. The company’s portfolio spans therapies used in oncology, inflammation, cardiovascular conditions, osteoporosis, and rare diseases, making it a significant participant in global biopharmaceutical markets.
About Amgen, Inc.
Amgen Inc. Common Stock represents ownership in Amgen Inc., a biotechnology company focused on discovering, developing, manufacturing, and marketing human therapeutics for serious diseases. The company’s portfolio spans therapies used in oncology, inflammation, cardiovascular conditions, osteoporosis, and rare diseases, making it a significant participant in global biopharmaceutical markets. Amgen also supports its business through biologic manufacturing capabilities and a commercial organization that brings prescription medicines to patients and healthcare providers in multiple regions. As a large-cap healthcare equity, Amgen Inc. Common Stock is widely followed by market participants for its role in the biotechnology sector and its exposure to branded medicines, biologics, and specialty treatment areas.
CEO Mr. Robert A. Bradway · 31,500 employees · United States · https://www.amgen.com